Ublituximab

N/A

Report date: 2026/04/04 20:00:24

Base Information

Drug NameUblituximab
Drug Alias Name乌利妥昔单抗UblituximabumRituximab biobetter - TG Therapeutics乌妥昔单抗优必妥昔单抗 +[15] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsCentral Nervous System LymphomaRichter's SyndromeAutoimmune Diseases +[15] 
Global Approved IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/12/28
Country/TerritoryCzechiaBosnia and HerzegovinaBulgaria +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTg Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNeuraxpharm Pharmaceuticals SlIldong Pharmaceutical Co LtdNational Cancer Institute +[7] 
Inactive CompaniesWeill Medical College of Cornell UniversityJohns Hopkins UniversityUniversity Of Alabama At Birmingham +[4] 
Active IndicationsRichter's SyndromeAutoimmune DiseasesNeuromyelitis Optica +[8] 
Inactive IndicationsCentral Nervous System LymphomaWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, Diffuse +[7] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG